In studies of NSCLC patients receiving immunotherapy, the high-CNVA group presented elevated PD-L1, CD39, and CD19 expression levels, as well as increased infiltration levels of CD8+ T cells and CD3+ T cells. Here, ENTPD1 is linked to non-small cell lung carcinoma.